Hypercalcaemia of malignancy (HCM) is the most common metabolic complication seen in patients with cancer and is associated with a high degree of morbidity and mortality. It affects an estimated 2%-30% of patients and most frequently occurs in patients with breast, lung, and renal cancer, as well as multiple myeloma.

The...